Online Program

Return to main conference page

All Times EDT

Thursday, September 24
Thu, Sep 24, 3:00 PM - 4:15 PM
Virtual
Understanding Virtual Clinical Trials in the Digital Age: What Adjustments Do We Need to Incorporate into Clinical Trials?

Considerations for Virtual Clinical Trials in a Pandemic Outbreak (301242)

*Demissie Alemayehu, Pfizer Inc 
Kannan Natarajan, Pfizer Inc. 
Satrajit Roychoudhury, Pfizer Inc 

Keywords: Virtual clinical trial; site-less trial, decentralized trial, remote trial, analytics, machine learning, pandemic, COVID-19

While disruptive technology has made significant impacts in many areas, clinical drug development has been slower to embrace the emerging technology to enhance efficiency and optimize value in clinical trials. The topic has garnered even greater relevance in the face of the COVID-19 outbreak, which has caused unprecedented disruptions in the conduct of clinical trials and presented considerable challenges and opportunities for data analysts. The plausibility of conducting virtual clinical trials has been entertained as an attractive option to enhance efficiency in clinical development, and more importantly in offering patients easier and attractive means to participate in clinical trials. In this talk, we will highlight some of the potential opportunities with virtual clinical trials and offer statistical solutions to overcome some of the underlying issues. In addition, we will discuss potential applications of machine learning tools in study design and data acquisition, processing and analysis in a virtual trial setting.